Cardiol Therapeutics Files 6-K, Includes News Release
Ticker: CRDL · Form: 6-K · Filed: Sep 24, 2024 · CIK: 1702123
Sentiment: neutral
Topics: reporting, news-release
TL;DR
Cardiol Therapeutics filed a 6-K on 9/24/24 with a news release attached.
AI Summary
Cardiol Therapeutics Inc. filed a Form 6-K on September 24, 2024, reporting for the month of September 2024. The filing indicates that the company is a foreign private issuer and will file its annual reports under Form 20-F. The report includes Exhibit 99.1, which is a news release.
Why It Matters
This filing provides an update on Cardiol Therapeutics' reporting status and includes a news release, which may contain material information for investors.
Risk Assessment
Risk Level: low — This filing is a routine report (6-K) and does not appear to contain significant new financial or operational disclosures that would immediately alter risk.
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — Filer of the 6-K report
- September 2024 (date) — Reporting period for the 6-K
- 20240924 (date) — Filing date of the report
- Form 20-F (document) — Annual report form to be filed by the company
- Exhibit 99.1 (document) — Included news release
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report for the month of September 2024 and to submit an accompanying news release (Exhibit 99.1).
What is Cardiol Therapeutics Inc.'s filing status regarding annual reports?
Cardiol Therapeutics Inc. indicates it files or will file annual reports under cover of Form 20-F.
On what date was this Form 6-K filed?
This Form 6-K was filed on September 24, 2024.
What is included as an exhibit with this filing?
Exhibit 99.1, a news release, is submitted with this Form 6-K.
Where is Cardiol Therapeutics Inc. headquartered?
Cardiol Therapeutics Inc. is headquartered at 602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5.
Filing Stats: 224 words · 1 min read · ~1 pages · Grade level 13.5 · Accepted 2024-09-24 07:38:51
Filing Documents
- form6k.htm (6-K) — 6KB
- exhibit99-1.htm (EX-99.1) — 12KB
- exhibit99-1xu001.jpg (GRAPHIC) — 8KB
- 0001062993-24-016937.txt ( ) — 29KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CARDIOL THERAPEUTICS INC. (Registrant) Date: September 24, 2024 By: /s/ Chris Waddick Chris Waddick Title: Chief Financial Officer